Related Experiment Video
Updated: Jul 10, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
[Heparin-induced thrombocytopenia].
Ignacio Cruz-González1, María Sánchez-Ledesma, Pedro L Sánchez
1Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Revista Espanola De Cardiologia
|October 24, 2007
Summary
Heparin-induced thrombocytopenia (HIT) is a dangerous complication of heparin treatment. Early detection via platelet count monitoring and prompt cessation of heparin are crucial for managing HIT and preventing thrombosis.
Area of Science:
- Hematology
- Pharmacology
- Immunology
Background:
- Heparin is widely used but carries risks.
- Hemorrhage is a known complication.
- Heparin-induced thrombocytopenia (HIT) is a more severe risk.
Purpose of the Study:
- To review the diagnosis and treatment of heparin-induced thrombocytopenia (HIT).
- To highlight the risks associated with heparin therapy.
- To emphasize early detection and management strategies for HIT.
Main Methods:
- Review of literature on heparin-induced thrombocytopenia.
- Discussion of diagnostic criteria and laboratory assays.
- Outline of treatment protocols for HIT.
Main Results:
- HIT is caused by antibodies to the heparin-platelet factor 4 complex.
- Thrombocytopenia (platelet count <50% of baseline) occurs 5-14 days post-heparin initiation.
- HIT increases the risk of thrombotic complications.
Conclusions:
- Early monitoring of platelet counts in patients receiving heparin is essential.
- Diagnosis is confirmed by detecting heparin-dependent platelet activation.
- Discontinuation of heparin and alternative anticoagulation are critical upon HIT diagnosis or suspicion.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:05Introduction to Hemostasis
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...